Also known as: Ten63 Therapeutics
Ten63 Therapeutics is an advanced AI drug-discovery company that develops therapeutics for hard-to-drug targets using its BEYOND platform. The company focuses on computational discovery, molecule generation, and resistance prediction for oncology and infectious disease applications.
Biogen marked 30 years of U.S. manufacturing with a $2 billion RTP investment, while regional leaders urged deeper venture capital and research density to boost North Carolina's biotech competitiveness.
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
Ten63 Therapeutics announced strategic investment from Chugai Venture Fund and the Gates Foundation, bringing total funding to more than $45 million to advance its BEYOND AI drug discovery platform targeting previously undruggable proteins.
